NADAC acquisition cost data for METHAZOLAMIDE 25 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00574079001 | $1.95 | 2022-06-22 | Rx |
| 62559024001 | $1.95 | 2022-06-22 | Rx |
| 68682002210 | $1.95 | 2022-06-22 | Rx |
| 00574079001 | $1.95 | 2022-06-22 | Rx |
| 62559024001 | $1.95 | 2022-06-22 | Rx |
| 68682002210 | $1.95 | 2022-06-22 | Rx |
| 00574079001 | $1.95 | 2022-06-22 | Rx |
| 62559024001 | $1.95 | 2022-06-22 | Rx |
| 68682002210 | $1.95 | 2022-06-22 | Rx |
| 00574079001 | $1.95 | 2022-06-22 | Rx |
Generic: Methazolamide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.9M | 44,585 | 10,808 | $4.54 |
| 2020 | $17.8M | 41,786 | 9,956 | $4.53 |
| 2021 | $15.9M | 40,149 | 10,095 | $4.17 |
| 2022 | $14.5M | 40,862 | 10,131 | $3.74 |
| 2023 | $12.6M | 41,087 | 10,447 | $3.20 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $2.0M | 6,962 | 1,817 |
| New York | $1.7M | 5,197 | 1,223 |
| California | $1.5M | 5,289 | 1,824 |
| Texas | $660.0K | 2,129 | 624 |
| Massachusetts | $520.8K | 1,760 | 422 |
| Pennsylvania | $503.1K | 1,849 | 464 |
| Georgia | $495.3K | 1,458 | 368 |
| Illinois | $432.4K | 1,243 | 295 |
| Ohio | $421.5K | 1,460 | 343 |
| Michigan | $408.9K | 1,149 | 342 |
| North Carolina | $349.9K | 1,124 | 292 |
| Tennessee | $321.6K | 780 | 194 |
| South Carolina | $317.4K | 811 | 180 |
| New Jersey | $310.5K | 1,033 | 316 |
| Virginia | $254.9K | 798 | 209 |
| Missouri | $207.2K | 629 | 149 |
| Alabama | $187.7K | 696 | 148 |
| Puerto Rico | $172.9K | 517 | 105 |
| Maryland | $163.3K | 618 | 208 |
| Connecticut | $149.5K | 544 | 126 |
| Washington | $128.5K | 450 | 133 |
| Kentucky | $108.7K | 400 | 87 |
| Louisiana | $105.5K | 348 | 80 |
| Arizona | $104.8K | 290 | 96 |
| Indiana | $86.2K | 307 | 83 |
| New Hampshire | $78.3K | 212 | 61 |
| Wisconsin | $68.6K | 187 | 45 |
| Minnesota | $66.6K | 201 | 57 |
| Colorado | $61.8K | 211 | 65 |
| Utah | $54.2K | 142 | 38 |
| Nebraska | $51.2K | 157 | 44 |
| Hawaii | $50.2K | 176 | 50 |
| Oklahoma | $46.9K | 164 | 38 |
| Arkansas | $46.3K | 159 | 49 |
| Maine | $44.1K | 125 | 32 |
| Alaska | $40.0K | 110 | 24 |
| District of Columbia | $39.8K | 98 | 30 |
| Oregon | $37.1K | 116 | 40 |
| Iowa | $35.7K | 125 | 34 |
| Vermont | $34.3K | 100 | 31 |
| New Mexico | $31.6K | 105 | 38 |
| Kansas | $31.2K | 104 | 31 |
| Mississippi | $30.9K | 188 | 21 |
| Delaware | $21.8K | 81 | 16 |
| Nevada | $20.3K | 69 | 23 |
| Montana | $19.8K | 77 | 12 |
| Rhode Island | $19.8K | 105 | 20 |
| Virgin Islands | $16.4K | 60 | 15 |
| West Virginia | $11.8K | 53 | 23 |
| Idaho | $10.0K | 49 | 13 |
| South Dakota | $9.4K | 43 | 14 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.